SUMMIT-07 Results for NKTR-181 for Chronic lower back pain

SUMMIT-07 Results for NKTR-181 for Chronic lower back pain

The Results identified at the just concluded American Association of Nurse Practitioner Conference 2018, showed that taking a dose of 100 to 400mg of NKTR-181 twice a day, greatly reduced the pain of patients suffering mil to severe chronic low back pain without much adverse events.

Compared with the more standard opioids, NKTR-181 proves to be a rather novel,, full mu-opioid receptor agonist that provides a reduced rate of gaining access into the CNS (central nervous system)

SUMMIT-07 (with a identifier; NCT02362672) Included various participants with a variety of moderate to severe chronic back pain. These participants were opioid naive (total number(n) was 610). At random, the participants were assigned to either receive NKTR-181 treatment (n=309) or receive placebo treatment (n=301). The major primary end indicator was a weekly change in pain score from the base week up to week 12. The secondary end indicators were the percentage of completers with a week 12 pain score reduction ≥30% as well as ≥50%, and also adverse events.

At the 12th week, the NKTR-181 group had the least-squares mean change in the pain scores recorded weekly with a value of +0.92 compared to patients receiving placebo (P=0.0019) who had +1.46. This indicates a a significant analgesic effect with the treatment.

71.2% of participants in the NKTR group at week 12 had pain reductions of ≥30% while 51.5% had ≥50% pain reductions. In comparison to participants receiving placebo (P≤0.001), their respective figures were 57.1% and 37.9%

54.4% of participants reported Adverse events in the NKTR-181 group, while only 49.8% in the placebo group. Less than 3% instances where reported in the treatment group relating to adverse events and the Central nervous system.

For more information Fort Lauderdale Chiropractor


Chiropractor Pompano Beach, Back Pain Doctor Fort Lauderdale


Ready to make an appointment?

Contact us for a FREE initial Consultation